articleThe Journal of Experimental MedicineJan 13, 2003BRONZE OA

Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells

Hospital Base · University of Basel

PubMed
Indexed incrossrefpubmed

Abstract

T lymphocytes expressing the T cell receptor (TCR)-gammadelta recognize unknown antigens on tumor cells. Here we identify metabolites of the mevalonate pathway as the tumor ligands that activate TCR-gammadelta cells. In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate metabolites and recognition by TCR-gammadelta cells. When metabolite accumulation is induced by overexpressing HMGR or by treatment with nitrogen-containing bisphosphonate drugs, tumor cells derived from many tissues acquire the capacity to stimulate the same TCR-gammadelta population. Accumulation of mevalonate metabolites in tumor…

Citation impact

827
total citations
FWCI
9.39
Percentile
100%
References
31
Citations per year

Authors

6

Topics & keywords

Keywords
  • Mevalonate pathway
  • T-cell receptor
  • Biology
  • T cell
  • Immunotherapy
  • Antigen
  • Immune system
  • Cancer research
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.